In a nutshell
This article investigated the safety and effectiveness of pomalidomide (Pomalyst) for the treatment of relapsed or refractory (does not respond to treatment) multiple myeloma (RRMM) in a real-life setting. The authors concluded that this treatment is safe and effective in these patients.
Some background
Multiple myeloma (MM) is a cancer of plasma cells. These are a type of white blood cell normally responsible for producing antibodies. Bortezomib-based therapy is the standard treatment for these patients. However, there are many patients who are unresponsive to this treatment.
An alternative treatment is with pomalidomide. It works by stopping the growth of cancer cells. However, the effect on overall survival and safety of pomalidomide is still under investigation outside of clinical trials.
Methods & findings
This study involved 50 patients with RRMM. All patients received an average of 4 cycles of pomalidomide. Patients were followed up for an average of 9.5 months.
The overall response rate was 39.1%. Progression-free survival (the time it took for cancer to start growing again) was 10 months. Overall survival was 14 months.
9 patients needed a lower dose of pomalidomide due to side effects. The most common severe side effects included low white cell count (cells needed to fight infection; 24%), respiratory infections (14%), low platelet count (cells involved in blood clotting; 10%), and neuropathy (damage to the nerves of the hands and feet; 4%)
The bottom line
The study concluded that pomalidomide is safe and effective in patients with RRMM.
The fine print
This study had a rather small number of patients and a short follow up period. Further studies are needed.
Published By :
European Journal of Haematology
Date :
Aug 18, 2018
